Dr. Figlin on remaining questions from KEYNOTE-564 trial of adjuvant pembrolizumab in RCC

Video

Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, discusses remaining questions from the phase 3 KEYNOTE-564 trial, which was presented at the 2021 ASCO Annual Meeting (LBA5). The study findings showed that adjuvant pembrolizumab (Keytruda) led to a significant reduction in the risk of disease recurrence or death versus placebo in patients with clear cell renal cell carcinoma. In the video, Figlin shares his expert observations on important questions that still remain, despite the positive results of the trial.

Related Videos
Dr. Sunil H. Patel in an interview with Urology Times
medical depiction of a human bladder
Dr. Sunil H. Patel in an interview with Urology Times
© 2023 MJH Life Sciences

All rights reserved.